TAP Uprima
Executive Summary
Takeda/Abbott joint venture hopes to meet with FDA during second quarter to discuss next steps in development of erectile dysfunction therapy Uprima (apomorphine). In January, Abbott said that TAP expected to meet with FDA during the first quarter to discuss the Uprima NDA, which was withdrawn in June (1"The Pink Sheet" Jan. 22, p. 16)